News
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces closing of $6 million offering with healthcare investor. Proceeds for working capital. AGP/Alliance acted as placement agent -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close
NanoViricides, Inc. announces securities purchase agreement for $6 million registered direct offering. Proceeds for working capital and corporate purposes -
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo
NanoViricides, Inc. receives approval to start Phase II Clinical Trial of NV-387 for MPox treatment in the DRC. NV-387 shows promise as a broad-spectrum antiviral drug -
-
